 |
|
Targeted Treatment of Active Trachoma
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: Dr Atik and colleagues1 studied the prevalence of active trachoma and ocular Chlamydia trachomatis infection in 3 Vietnamese communes. Two communes (Surgery for trachomatous trichiasis; Antibiotics for Chlamydia trachomatis infection; [SA], and Surgery for trachomatous trichiasis; Antibiotics for Chlamydia trachomatis infection; Facial cleanliness; Environmental improvement [SAFE])were selected to receive azithromycin using a targeted approach in which schoolchildren aged 5 to 15 years with signs of active trachoma and their household contacts were treated. A third commune that did not receive oral antibiotics served as a control. Because no association was found between clinical signs and the presence of ocular C trachomatis infection, only a small proportion of infected individuals was treated with azithromycin: 4% and 11% of the 2 SA and SAFE communes, respectively, at baseline; and 0% and 10% at 1 year.
The prevalence of active trachoma declined in all 3 communes from greater than 5% . . . [Full Text of this Article]
David Mabey, MD
David.mabey@lshtm.ac.uk
Robin Bailey, MD, PhD;
Anthony Solomon, MB, BS, PhD
Clinical Research Unit
Matthew Burton, MD, PhD;
Clare Gilbert, MD;
Allen Foster, MD
International Centre for Eye Health
London School of Hygiene & Tropical Medicine
London, England
Thomas Lietman, MD, PhD
Francis I. Proctor Foundation
University of California, San Francisco
Sheila West, PhD
Wilmer Eye Institute
Johns Hopkins Medical Institutions
Baltimore, Md
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Caution: chlamydia surveillance data ahead
Low
Sex. Transm. Infect. 2008;84:80-81.
FULL TEXT
|
